Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of hepatitis-C-focused biotech technology company Idenix Pharmaceuticals
So what: Earlier this month, the FDA put an indefinite halt on IDX184, Idenix's lead compound, due to complications arising from Bristol-Myers Squibb's
Now what: Another day, another setback for Idenix. Gilead Sciences
Craving more input? Start by adding Idenix Pharmaceuticals to your free and personalized Watchlist so you can keep up on the latest news with the company.